Brain Cancer Therapeutics Market to Hit USD5.1 Billion by 2030 Due to Increasing Incidence of Brain Tumors

• Overview
• Table of Content
• Research Methodology
• Download Free Sample

The Global Brain Cancer Therapeutics Market size was valued at around USD3.3 billion in 2024 and is projected to reach USD5.1 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 7.3% during the forecast period, i.e., 2025-30, cites Markntel Advisors in the recent research report. An increase in brain cancer incidence is one of the major factors pushing the market higher. Based on statistics published by the National Brain Tumor Society (NBTS), it is estimated that in the United States, around 94,390 persons were diagnosed with a primary brain tumor in 2023. Research and development in this area have seen highs with the continuous flow of investment from the government and private entities directed toward novel treatment discoveries. Globally, various governments are spreading awareness regarding brain cancer and the therapies required for the cure through multiple initiatives. For instance, with maximized investments in research and development, the Canadian government collaborated with the Brain Tumor Foundation to further promote brain cancer therapies through various awareness drives.

Dabrafenib in combination with trametinib has been approved not only for the treatment of melanoma but also for the treatment of other solid tumors, making it a significant market trend. The FDA has also cleared it for advanced solid tumors that have specific genetic mutations. Also, emerging technologies such as digital imaging software are enhancing the diagnosis and treatment of brain cancers. Advanced imaging techniques, together with minimally invasive surgical procedures, are on the rise. Additionally, personalized medicine becomes more trendy as targeted therapies are available that uniquely tailor treatment by using the genetic profiles of individual patients, enhancing the efficacy of treatments. Also, the emerging markets in the Asia-Pacific region and Latin America show enormous potential for growth due to rising awareness and a boom in healthcare infrastructure.

However, a few challenges impede the market growth. The high cost associated with various treatments like radiation therapy, surgery, and other newly targeted therapies causes major barriers for the patients. Also, the extensive side effects associated with current treatments further hinder the market growth. Additionally, navigating the regulatory landscape for new therapies can be challenging and time-consuming, potentially delaying the availability of new treatments, further states the research report, “Global Brain Cancer Therapeutics Market Analysis, 2025,”

Global Brain Cancer Therapeutics Market Segmentation Analysis 

Immunotherapy Highly Preferred Option in the Market

Based on the therapy, the market is further bifurcated into chemotherapy, immunotherapy, targeted therapy, and others. The immunotherapy segment dominates the market with the largest market share, around 43%. This uniqueness in cancer treatment and immune system activation accounts for the normal view. Immunotherapy is the reprogramming of the immune system to make it start targeting and killing cancer cells. Immune checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines are gradually developing to increase survival and the quality of life for brain tumor patients. In addition to this, greater side effects when compared to conventional therapies like chemotherapy enhance the trend of immunotherapy. For that reason, immunotherapy is the first and best treatment option for brain cancer that will continue to lead the market growth.

North America Leads the Brain Cancer Therapeutics Industry Globally

North America leads the global brain cancer therapeutics industry with a market share of around 60%. Its dominance could be attributed to advanced healthcare infrastructure and extensive research and development spending. Many of the major academic institutions and pharmaceutical companies across the U.S. are working on targeted therapies intended for brain cancer treatment. Also, the market growth pattern gets added impetus from many supportive government initiatives, which include more funding for cancer research and accelerated drug approvals. Moreover, there is growing awareness of brain cancer, and the corresponding rise in diagnosis rates, which further augments regional market growth. All these factors combined help North America to dominate the Global Brain Cancer Therapeutics Market, paving the path for advancements in patient care.

Competitive Landscape

With strategic initiatives, such as mergers, collaborations, and acquisitions, the leading market companies, including Amgen Inc., AstraZeneca PLC, Bayer AG, Kazia Therapeutics Ltd., Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., GSK plc, Johnson & Johnson, Merck & Co. Inc. Novartis AG, Pfizer Inc., Bristol-Myers Squibb Company, Genentech, Inc., NantOmics, Thermo Fisher Scientific Inc. and others are looking forward to strengthening their market positions.

Key Questions Answered in the Research Report

1. What are the industry’s overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares)?
2. What are the trends influencing the current scenario of the market?
3. What key factors would propel and impede the industry across the globe?
4. How has the industry been evolving in terms of geography & solution adoption?
5. How has the competition been shaping up across the regions?
6. How have buying behavior, customer inclination, and expectations from product manufacturers been evolving during 2020-30?
7. Who are the key competitors, and what strategic partnerships or ventures are they coming up with to stay afloat during the projected time frame?